miRview mets is designed to identify the primary tumor site in patients with metastatic cancer.

Rosetta Genomics is offering a second diagnostic, miRview™ mets, through its CLIA-certified lab in Philadelphia. The test identifies 25 different tumor types including colon, brain, breast, kidney, liver, lung, ovary, pancreas, prostate, and testis. It measures the expression level of 48 miRNA biomarkers in the tumor.

On December 12, Rosetta Genomics launched miRview™ squamous to help distinguish between squamous and nonsquamous non-small-cell lung cancer.

The company expects miRview™ meso, a test differentiating mesothelioma from adenocarcinoma in the lung, to be commercially available by the end of 2008.

“In contrast to current methods for identifying a metastasis’ origin, which may include a wide range of costly, time consuming, and at times inefficient tests, miRview mets provides the physician with an accurate identification of the tumor’s origin,” according to Ranit Aharonov, Ph.D., evp R&D, head of computational biology at Rosetta Genomics. “We have designed miRview mets so that it follows a clear biological rationale, and it utilizes a relatively small number of molecular markers, which makes it both a robust and a transparent assay.”

Previous articlePressure BioSciences Gains Patents from Battelle to Advance Use of Pressure Cycling Technology
Next articleProgen and Avexa to Merge with Focus on Cancer and Infectious Diseases